- Home
- / Janux Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Janux Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$54.2
2024-10-29
Market Capitalization
$2.8 B
2024-10-29
Revenue
$10 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 3.6M | 8.6M | 8.1M | 10.6M | 10.0M |
| General and administrative expense | 10.3M | 22.3M | 26.1M | 41.0M | 41.8M |
| Operating expense total | 36.6M | 75.7M | 109.4M | 167.7M | |
| EBIT | (32.9M) | (67.1M) | (73.0M) | (98.8M) | (157.7M) |
| EBIT margin, % | -905.4% | -779.0% | -933.6% | -1576.7% | |
| Interest income | 257.0K | 4.0M | 14.7M | 29.9M | 44.0M |
| Net Income | (32.7M) | (63.1M) | (58.3M) | (69.0M) | (113.6M) |
| EPS | (1.5) | (1.0) | (1.3) | (1.8) |